stockrowNeurocrine Biosciences, Inc. (NBIX) vs Viatris Inc. (VTRS)
- Neurocrine Biosciences, Inc. NBIX 163.45 +2.31%
- Viatris Inc. VTRS 19.40 +2.27%
Neurocrine Biosciences, Inc. and Viatris Inc. are both Drug Manufacturers Specialty & Generic companies. Viatris Inc. is the larger, with a market value of $21.8B against $16.2B — 1.3× the size. Viatris Inc. has negative trailing earnings, so its P/E is not meaningful; Neurocrine Biosciences, Inc. trades at 23.0×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 38.0% against 4.27%. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs −4.13%) and the higher return on invested capital (17.7% vs −0.02%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 15 and Viatris Inc. on 6.
Valuation
Profitability
| Metric | NBIX | VTRS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.75% | 35.31% | 53.51% |
| Operating margin | 23.96% | (0.03%) | 0.00% |
| Net margin | 18.98% | (4.13%) | (2.45%) |
| Free cash flow margin | 28.09% | 16.27% | 0.00% |
| Return on equity | 20.41% | (4.21%) | (0.80%) |
| Return on assets | 14.20% | (1.67%) | (1.67%) |
| Return on invested capital | 17.65% | (0.02%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack